JPRN-UMIN000003078已完成未知
Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of omeprazole 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an index - Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis
Japan Dyspepsia Society0 个研究点目标入组 220 人开始时间: 2010年1月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with a history of gastrointestinal resection or vagotomy (2)Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss (3)Patients with peptic ulcer (except those in scarring stage) (4)Patients with a history of, or who currently have, any of the following diseases: •Zollinger-Ellison syndrome •Inflammatory Bowel Disease (IBD) •Irritable Bowel Syndrome (IBS) •Esophageal stricture •Esophageal achalasia •Malabsorption •Cerebrovascular disorders such as cerebral hemorrhage and cerebral infarction (5)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. (6)Patients with a confirmed, or suspected, malignant lesion (7)Women who are pregnant or who may possibly be pregnant, and lactating mothers (8)Patients who require continued treatment with drugs (atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole, and antacids containing aluminium hydroxide gel and magnesium hydroxide) which may interact with the study drugs (9)Patients receiving treatment with proton pump inhibitors, H2-receptor antagonists, prokinetic agents, gastric mucosa protective agents, anticholinergics, antacids, antidepressants, antianxiety agents, antidiabetic drugs, steroids (excluding external preparations), non-steroid anti-inflammatory drugs (NSAIDs), aspirin preparations including low-dose aspirin and/or bisphosphonate drugs. However, patients who discontinue using these drugs for at least 1 week prior to the symptom survey or switch to another treatment, may enrol in the study. (10)Other patients whom the investigator considers unsuitable for admission to the study
研究者
相似试验
已完成
不适用
Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized double-blind comparative study of esomeprazole 20mg vs. rabeprazole 10mgJPRN-UMIN000010450Juntendo University School of Medicine, Department of Gastroenterology and Hepatology200
已完成
不适用
Study of the improvement effect of proton pump inhibitors for gastric ulcers after endoscopic submucosal dissection (ESD): a randomized comparative study of omeprazole iv vs. esomeprazole pogastric cancerJPRN-UMIN000010958Department of Gastroenterology, Ishikawa Prefectural Central Hospital200
已完成
不适用
Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized comparative study of omeprazole 20mg vs. rabeprazole 10mg using the time (number of days) to improvement in symptoms as an indexreflux esophagitisJPRN-UMIN000002955Japan Dyspepsia Society220
招募中
Unknown
Investigation of the usefulness of Rikkunshi-to in functional dyspepsiFunctional DyspepsiaJPRN-jRCT1061220076Yachida Tatsuo90
招募中
3 期
Comparison of the effect of baclofen and proton pump inhibitors in patients with gastroesophageal reflux diseasegastroesophageal reflux disease.Gastro-esophageal reflux diseaseIRCT20210308050634N1Islamic Azad University60